Skip to main content

Get Your Patients Started Today!

Healthcare provider holding the CeQur Simplicity patch

CeQur Simplicity™ is a wearable mealtime insulin patch that can be worn up to 7 days.

Available in 1U and 2U dosing options, it’s clinically proven to reduce patients’ A1C and increase time-in-range.1,2

Why Prescribe the CeQur Simplicity Wearable Insulin Patch?

Patients that use the CeQur Simplicity wearable insulin patch are more likely to adhere to their insulin regimen and achieve glycemic targets.

CeQur Simplicity is simplifying mealtime insulin delivery for T1 and T2 diabetes patients on multiple daily injections (MDIs). Our insulin patch that can be worn for up to 7 days removes mealtime insulin barriers, providing a convenient, discreet, and injection-free way for people with diabetes to deliver mealtime and correction boluses.1

CeQur Simplicity on the Abdomen
Convenient

Can be worn for up to seven days1

Water-resistant4

Holds up to 240 units of rapid-acting insulin1

Easy to use and learn, <30 minutes of training3

Discreet

Can be worn and dosed under clothing

One click administers 1 unit or
2 units of insulin 

Thin (<4 stacked quarters), compact (65 x 36 mm), and lightweight (10 gm)

CeQur Simplicity Under the Shirt
Injection-Free

Less pain encourages adherence1

Clinically shown to reduce A1C, increase TIR1,2

One patch replaces up to twenty-one mealtime injections

Small, flexible cannula for painless insulin delivery1

The CeQur Simplicity wearable insulin patch is intended for subcutaneous, bolus delivery of insulin for the management of diabetes mellitus in adults over 21 years of age requiring insulin. The patch is not intended for pediatric patients and does not replace the need for basal insulin.

CeQur Simplicity Extended Wear Insulin Patch

CeQur Simplicity is Easy to Teach and Use

Getting patients started with CeQur Simplicity is easy. Most patients need <30 minutes of training and feel fully confident applying the patch after just 1-3 times. Healthcare professionals also found that training patients to use the patch was easy.3

Patients follow these simple steps to begin using the CeQur Simplicity wearable insulin patch, which can be worn for up to 7 days.

Fill the patch with up to a 7-day supply of insulin. CeQur Simplicity holds up to 240 units of rapid-acting insulin.*

*Labeled for use with Humalog® U-100 and NovoLog® U-100

1

Use the Inserter to apply the patch to the abdomen for up to seven days of wear and injection-free dosing

2

Remove the Inserter, and the patch is ready to dose.

3

The CeQur Simplicity wearable insulin patch holds up to 240 units of rapid-acting insulin and is available in 1-unit or 2-unit dosing options.1

Built-in safety features ensure proper dosing and quickly build patient comfort.

Two-button safety mechanism prevents accidental dosing. Buttons lock in “locked-in” position when reservoir is empty or cannula is occluded4

Audible and tactile feedback indicates the 1-unit or 2-unit delivery4

Water-resistant to a depth of 1 meter for up to 30 minutes4

Our Wearable Insulin Patch is
Proven Reliable and Effective

CeQur Simplicity is clinically shown to improve glycemic control, which can reduce risk of long-term health complications.1,2

Baseline
Week 24
Week 44

After 24 weeks patients decreased their A1C an average of 1.7% and increased time-in-range (TIR) by 50%1,2 
Results were comparable to pens. Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure

The International Consensus on Time-in-range defines clinical target for TIR > 70%, which is evidenced to be the equivalent to an A1C < 7%5

Healthcare Professionals and Patients Prefer CeQur Simplicity

Healthcare professionals prefer the patch to a pen when advancing people with diabetes from basal to basal/bolus insulin management.

We Have You and Your Patients Covered

CeQur Simplicity is covered on most commercial and Medicare Part D insurance plans as a pharmacy benefit.

Eligible patients† may pay $0 for a 30-day supply of CeQur Simplicity Extended Wear Products. Learn more at CeQur Simplicity Copay Savings.

For additional questions, contact the CeQur CaresTM Team at 1-888-552-3787.

How to get patients started with the CeQur Simplicity wearable insulin patch:

Prescribe CeQur Simplicity 1U or 2U patch

Prescribe CeQur Simplicity Inserter

Prescribe a vial of rapid-acting insulin – labeled for use with Humalog® U-100 or NovoLog® U-100

Ensure patients schedule their training session to get started. Training must occur prior to first usage. A healthcare provider from your office or a CeQur Cares healthcare professional can train the patient. Have patients contact the CeQur Cares Team at 1-888-552-3787 or info@cequr.com.

Healthcare Professional Resources

Patient Resources

Quick Start Training Video

Learn more by viewing the CeQur Simplicity video of your specific Patch

Quick Start Guide

Get started fast using these easy-to-follow steps of your specific Patch

Read technical specifications and in-depth information of your specific Patch

Important Reminders Card

Learn how to count units with a Patch so you always get the right dose.

Patient Brochure

Find out why users prefer our wearable insulin Patch to pens or syringes.

Patch Tips

Use these tips to ensure a successful application of your CeQur Simplicity Patch

We’re Here to Help You and Your Patients Get Started

Call Us
Email Us

Get Your Patients Started Today

We respect the importance of your privacy and understand your health is a very personal and sensitive subject. CeQur Simplicity wants you to understand how it will use the information provided by you on this registration page. By clicking the “Submit” button above, you are indicating that CeQur Simplicity or its partners may use your information for program improvements, quality monitoring, data and analytics for commercial purposes, and future marketing communications. You also understand that you may opt out from receiving any future communications from CeQur Simplicity or its partners by clicking the “unsubscribe” link within any email you receive, or by calling 1-888-552-3787.

To better understand how CeQur Simplicity values your privacy, please see our Privacy Policy.

References

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.

2. Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167-1173.Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.

3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA

4. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.

5. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603.

6. Isaacs D, Kruger DF, Shoger E, Chawla H. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2023;41(2):198-207.

Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.
† For eligible, commercially insured patients. These offers are not valid for use by cash-paying patients or patients enrolled in Medicare, Medicaid, and TRICARE or other federal or state programs. Not valid where prohibited by law. Offers are subject to quantity limitations and maximum benefit amounts per fill apply. CeQur® reserves the right to rescind, revoke, or amend this offer without notice.